STOCK TITAN

[SCHEDULE 13G/A] Evolus, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Perceptive Advisors LLC, its managing member Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 2,474,843 shares of Evolus, Inc. common stock, representing 3.8% of the outstanding class based on 64,685,419 shares outstanding as stated in the filing. The holdings are reported as shared voting and shared dispositive power; none of the Reporting Persons claim sole voting or sole dispositive power. The filing states the Master Fund directly holds the shares and Perceptive Advisors acts as its investment manager, with Mr. Edelman as managing member.

Perceptive Advisors LLC, il suo socio accomandatario Joseph Edelman e il Perceptive Life Sciences Master Fund, Ltd. dichiarano la proprietà effettiva di 2.474.843 azioni di capitale ordinario di Evolus, Inc., pari al 3,8% della classe in circolazione sulla base di 64.685.419 azioni totali indicate nella documentazione. Le partecipazioni sono riportate come condivisione del diritto di voto e del diritto dispositvo; nessuno dei soggetti segnalanti dichiara poteri esclusivi di voto o dispositivi. Il deposito precisa che il Master Fund detiene direttamente le azioni e che Perceptive Advisors svolge la funzione di gestore degli investimenti, con il sig. Edelman quale socio accomandatario.

Perceptive Advisors LLC, su socio gestor Joseph Edelman y el Perceptive Life Sciences Master Fund, Ltd. informan la propiedad beneficiaria de 2.474.843 acciones de acciones ordinarias de Evolus, Inc., que representan el 3,8% de la clase en circulación según 64.685.419 acciones en circulación indicadas en el informe. Las tenencias se declaran con poder de voto compartido y poder dispositvo compartido; ninguno de los sujetos informantes reclama poder de voto ni poder dispositvo exclusivo. El documento indica que el Master Fund posee directamente las acciones y que Perceptive Advisors actúa como su gestor de inversiones, con el Sr. Edelman como socio gestor.

Perceptive Advisors LLC와 그 운용책임자 Joseph Edelman, 및 Perceptive Life Sciences Master Fund, Ltd.는 Evolus, Inc.의 보통주 2,474,843주에 대한 실질적 소유를 신고했으며, 이는 신고서에 기재된 유통주식수 64,685,419주를 기준으로 유통주식의 3.8%에 해당합니다. 보유 주식은 의결권과 처분권이 공유되는 것으로 보고되었으며; 보고자 중 누구도 단독 의결권이나 단독 처분권을 주장하지 않았습니다. 제출서류에는 마스터펀드가 해당 주식을 직접 보유하고 있으며 Perceptive Advisors가 투자운용사로서 역할을 하고, Edelman 씨가 운용책임자(매니징 멤버)로 기재되어 있다고 명시되어 있습니다.

Perceptive Advisors LLC, son membre gérant Joseph Edelman et le Perceptive Life Sciences Master Fund, Ltd. déclarent la propriété bénéficiaire de 2 474 843 actions d'actions ordinaires d'Evolus, Inc., représentant 3,8 % de la catégorie en circulation sur la base de 64 685 419 actions en circulation indiquées dans le dépôt. Les participations sont déclarées avec pouvoir de vote partagé et pouvoir de disposition partagé ; aucun des déclarants ne revendique un pouvoir de vote ou de disposition exclusif. Le dépôt précise que le Master Fund détient directement les actions et que Perceptive Advisors agit en tant que gestionnaire d'investissement, M. Edelman étant le membre gérant.

Perceptive Advisors LLC, sein geschäftsführendes Mitglied Joseph Edelman und der Perceptive Life Sciences Master Fund, Ltd. melden das wirtschaftliche Eigentum an 2.474.843 Aktien der Stammaktien von Evolus, Inc., was nach den in der Einreichung genannten 64.685.419 ausstehenden Aktien 3,8% der ausstehenden Aktienklasse entspricht. Die Bestände werden mit gemeinsamem Stimmrecht und gemeinsamem Verfügungsrecht angegeben; keiner der meldenden Personen beansprucht alleiniges Stimm- oder Verfügungsrecht. Die Einreichung legt dar, dass der Master Fund die Aktien direkt hält und Perceptive Advisors als dessen Investmentmanager fungiert, wobei Herr Edelman als geschäftsführendes Mitglied genannt ist.

Positive
  • Full disclosure of ownership structure including manager, fund, and individual reporting persons
  • Clear numeric stake disclosed: 2,474,843 shares representing 3.8% of the class
  • Classification as shared voting and dispositive power removes ambiguity about control attribution
Negative
  • No sole voting or dispositive power—the Reporting Persons lack individual control over the shares

Insights

TL;DR A 3.8% disclosed stake by a specialized investment manager is material but non-controlling.

Perceptive's reported 2.47M shares equals 3.8% of Evolus based on the stated share count, positioning the group as a meaningful minority holder without sole voting authority. Shared voting and dispositive power indicate coordinated influence via the Master Fund and Perceptive Advisors rather than direct control. This level of ownership typically warrants monitoring for future changes in position, but by itself does not trigger control presumptions.

TL;DR Reporting shows clear disclosure of beneficial ownership with no indication of intent to seek control.

The Schedule 13G amendment correctly identifies the reporting persons and classifies the interest as shared voting/dispositive power. The certification asserts the holdings are not for the purpose of changing control, aligning with Schedule 13G treatment. Because there is no sole voting or dispositive power and ownership is under 5%, governance implications are limited unless future filings show accumulation or coordinated action with other holders.

Perceptive Advisors LLC, il suo socio accomandatario Joseph Edelman e il Perceptive Life Sciences Master Fund, Ltd. dichiarano la proprietà effettiva di 2.474.843 azioni di capitale ordinario di Evolus, Inc., pari al 3,8% della classe in circolazione sulla base di 64.685.419 azioni totali indicate nella documentazione. Le partecipazioni sono riportate come condivisione del diritto di voto e del diritto dispositvo; nessuno dei soggetti segnalanti dichiara poteri esclusivi di voto o dispositivi. Il deposito precisa che il Master Fund detiene direttamente le azioni e che Perceptive Advisors svolge la funzione di gestore degli investimenti, con il sig. Edelman quale socio accomandatario.

Perceptive Advisors LLC, su socio gestor Joseph Edelman y el Perceptive Life Sciences Master Fund, Ltd. informan la propiedad beneficiaria de 2.474.843 acciones de acciones ordinarias de Evolus, Inc., que representan el 3,8% de la clase en circulación según 64.685.419 acciones en circulación indicadas en el informe. Las tenencias se declaran con poder de voto compartido y poder dispositvo compartido; ninguno de los sujetos informantes reclama poder de voto ni poder dispositvo exclusivo. El documento indica que el Master Fund posee directamente las acciones y que Perceptive Advisors actúa como su gestor de inversiones, con el Sr. Edelman como socio gestor.

Perceptive Advisors LLC와 그 운용책임자 Joseph Edelman, 및 Perceptive Life Sciences Master Fund, Ltd.는 Evolus, Inc.의 보통주 2,474,843주에 대한 실질적 소유를 신고했으며, 이는 신고서에 기재된 유통주식수 64,685,419주를 기준으로 유통주식의 3.8%에 해당합니다. 보유 주식은 의결권과 처분권이 공유되는 것으로 보고되었으며; 보고자 중 누구도 단독 의결권이나 단독 처분권을 주장하지 않았습니다. 제출서류에는 마스터펀드가 해당 주식을 직접 보유하고 있으며 Perceptive Advisors가 투자운용사로서 역할을 하고, Edelman 씨가 운용책임자(매니징 멤버)로 기재되어 있다고 명시되어 있습니다.

Perceptive Advisors LLC, son membre gérant Joseph Edelman et le Perceptive Life Sciences Master Fund, Ltd. déclarent la propriété bénéficiaire de 2 474 843 actions d'actions ordinaires d'Evolus, Inc., représentant 3,8 % de la catégorie en circulation sur la base de 64 685 419 actions en circulation indiquées dans le dépôt. Les participations sont déclarées avec pouvoir de vote partagé et pouvoir de disposition partagé ; aucun des déclarants ne revendique un pouvoir de vote ou de disposition exclusif. Le dépôt précise que le Master Fund détient directement les actions et que Perceptive Advisors agit en tant que gestionnaire d'investissement, M. Edelman étant le membre gérant.

Perceptive Advisors LLC, sein geschäftsführendes Mitglied Joseph Edelman und der Perceptive Life Sciences Master Fund, Ltd. melden das wirtschaftliche Eigentum an 2.474.843 Aktien der Stammaktien von Evolus, Inc., was nach den in der Einreichung genannten 64.685.419 ausstehenden Aktien 3,8% der ausstehenden Aktienklasse entspricht. Die Bestände werden mit gemeinsamem Stimmrecht und gemeinsamem Verfügungsrecht angegeben; keiner der meldenden Personen beansprucht alleiniges Stimm- oder Verfügungsrecht. Die Einreichung legt dar, dass der Master Fund die Aktien direkt hält und Perceptive Advisors als dessen Investmentmanager fungiert, wobei Herr Edelman als geschäftsführendes Mitglied genannt ist.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/14/2025
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:08/14/2025
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/14/2025

FAQ

What stake does Perceptive Advisors report in Evolus (EOLS)?

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund report beneficial ownership of 2,474,843 shares, equal to 3.8% of the class.

Does Perceptive or Joseph Edelman have sole voting control of the reported EOLS shares?

No. The filing reports 0 sole voting power and 2,474,843 shared voting power for each Reporting Person.

Is the Perceptive stake in EOLS reported as intended to change control of the company?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control.

How was the 3.8% ownership percentage calculated in the filing?

The percentage is based on 64,685,419 shares outstanding as reported in the issuer's referenced quarterly report.

Which entity directly holds the reported Evolus shares?

The filing states the Master Fund directly holds 2,474,843 shares and Perceptive Advisors serves as its investment manager.
Evolus

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Latest SEC Filings

EOLS Stock Data

435.33M
54.73M
5.45%
91.35%
20.85%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NEWPORT BEACH